Immune Check Activators- Competitive Landscape, Technology and Pipeline Analysis, 2016

  • ID: 3774304
  • Drug Pipelines
  • 121 pages
  • DelveInsight
UP TO OFF
until Dec 31st 2018
1 of 4

FEATURED COMPANIES

  • Agenus
  • Apexigen
  • Genentech
  • Incyte Corporation
  • Kymab
  • MedImmune LLC
  • MORE
Our report deals with the TNFR/TNF superfamily members as agents of Cancer Immunotherapy that have brought a new dawn upon the existing therapies for cancer. Controlling diverse facets of immune function, it has brought into application a technology that rested in the pipeline for years. In the present scenario, members of the TNFR/TNF superfamily are being targeted to maintain, modulate and regulate body’s own immune system to fight cancer. The rationale of this therapy is to mitigate/ avoid side effects, resistance, toxicity and pain brought by the combination therapy of surgery, radiation and chemotherapy. The future of this therapy lies strong as will be seen before 2020 as majority of its products will show results on safety, efficacy and dosing as they move to their Phase II trials in the provided timeline.

Note: This report will be delivered to the client in 48 hours

Report Highlights

- Immune Checkpoint Activators Therapy Pipeline scenario
- Collaborations & partnering deals
- Current Prominent Research Areas and Key Players
- Pipeline product profiles Immune Checkpoint Activators Technologies and Targeted Antigens
- Licensing opportunities
- Market Drivers and Barriers
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Agenus
  • Apexigen
  • Genentech
  • Incyte Corporation
  • Kymab
  • MedImmune LLC
  • MORE
Table of Contents

1 Executive Summary
2 Executive Summary Snapshot
3 Immune checkpoints Activator Overview
- Rationale for targeting Immune checkpoint Agonist in oncology
- Stimulatory checkpoint molecules
- Advantages of Immune checkpoint Activators
- Constraints of Immune Checkpoint Activators
- Future of Immune Checkpoint Activators in Cancer Therapy
4 ImmuneCheck Activators Analysis
- ImmuneCheck Activators- Market Analysis
- Collaborations and Deals
- Companies received Grants for Immune checkpoints Activator
- Companies Investment Details for Future Development
- Licensing Opportunities
5 Market Drivers
6 Market Barriers
- ImmuneCheck Activators - Pipeline Analysis
- Number of Products
- Therapeutic Areas Targeted
- Stagesof Development
- Companies Involved
- Technological Platform Utilized
- Clinical Trials Analysis
- Clinical Products and Study Completion Year
- Phase II Drug: Trials Status and Completion Year
- Phase I Drugs:Trials Status and Completion Year
- Studies Analysisfor the Key Targets Antigens
7 Pipeline Therapeutics
- Therapeutics under Development by Companies
8 Late Stage Products (Phase III)
- Comparative Analysis
9 Mid Stage Products (Phase II)
- Comparative Analysis
10 Early Stage Products (Phase I and IND)
- Comparative Analysis
11 Pre-Clinical and Discovery Products
- Comparative Analysis
12 Therapeutic Assessment
- Assessment by Monotherapy Products
- Assessment by Combination Products
- Assessment by Route of Administration
- Assessment by Molecule Type
- Assessment by Stage and Molecule Type
Appendix
Consulting Services
About us
Contact Us
Disclaimer

List of Tables

Table 1: B7 & CD28 Family Members
Table 2: Collaboration and Deal Values for Immune checkpoints Activators, 2016
Table 3: Companies of Immune checkpoints Activators received grants, 2016
Table 4: Companies Investment Details for Immune checkpoints Activators, 2016
Table 5: ImmuneCheck Targets-Number of Drugs (N) and Indications
Table 6: ImmuneCheck Targets-Number of Drugs (N) and Indications
Table 7: ImmuneCheck Activators Targets Antigens and Companies
Table 8: ImmuneCheck Targets-Number of Trials (N) and Study Completion Year
Table 9: Number of Products Under Development for Immune checkpoints Activator, 2016
Table 10: Number of Products under Development by Companies, 2016
Table 11: Mid Stage Products (Phase II),2016
Table 12: Early Stage Products (Phase I and IND), 2016
Table 13:Pre-Clinical and Discovery Products, 2016
Table 14: Assessment by Monotherapy Products,2016
Table 15: Assessment by Combination Products, 2016
Table 16: Assessment by Route Of Administration, 2016
Table 17: Assessment by Stage and Route Of Administration, 2016
Table 18: Assessment by Molecule Type, 2016
Table 19:Assessment by Stage and Molecule Type, 2016

List of Figures

Figure 1: ImmuneCheck Activators -Companies and Collaborations (N) and Investment (Million)
Figure 2: ImmuneCheck Targets-Number of Products (N) and Total Share(%)
Figure 3: ImmuneCheck Targets-Number of Drugs (N) and Indications
Figure 4: ImmuneCheck Targets-Number of Products (N) and Stages of Development
Figure 5: ImmuneCheck Targets-Number of Products (N) and Stages Of Development
Figure 6: ImmuneCheck Targets-Number of Products (N) and Technology Used
Figure 7: ImmuneCheck Targets-Number of Products (N) and Technology used
Figure 8: ImmuneCheck Targets-Number of Trials (N) and Study Completion Year
Figure 9: ImmuneCheck Targets-Study Completion Date, Indication and Recruitment status.
Figure 10: ImmuneCheck Targets-Drugs and Study Completion Year
Figure 11: Number of Products under Development for Immune checkpoints Activator, 2016
Figure 12: Mid Stage Products (Phase II),2016
Figure 13:Early Stage Products (Phase I and IND), 2016
Figure 14:Pre-Clinical and Discovery Products,2016
Figure 15: Assessment by Monotherapy Products,2016
Figure 16: Assessment by Combination Products, 2016
Figure 17: Assessment by Route of Administration, 2016
Figure 18: Assessment by Stage and Route of Administration, 2016
Figure 19: Assessment by Molecule Type, 2016
Figure 20: Assessment by Stage and Molecule Type, 2016
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
- GlaxoSmithKline Pharmaceuticals
- Pfizer
- Genentech
- Five Prime Therapeutics
- Inhibrx
- Agenus
- Incyte Corporation
- Leap Therapeutics
- Agenus
- Apexigen
- Kymab
- Pfizer
- Genentech
- MedImmune LLC
Note: Product cover images may vary from those shown
5 of 4
Note: Product cover images may vary from those shown
Adroll
adroll